A double-blind comparison of intranasal budesonide with placebo for nasal polyposis.

Abstract

Intranasal budesonide, 400 micrograms two times a day, was evaluated in 36 patients referred for treatment of nasal polyposis. The age range was 20 to 68 years. Polypectomy was done 5.6 (mean) times previously. After a 5-week, treatment-free, baseline period, patients were treated in a double-blind fashion with either budesonide or placebo during 4 weeks. After this treatment period, placebo-treated patients started receiving budesonide in an open trial for an additional 4 weeks. The patients rated their nasal symptoms daily. Nasal examinations and nasal inspiratory flow rate (IFR) measurements were done at clinic visits. After 3 and 4 weeks of treatment, the response to budesonide was significantly greater than response to placebo. The greater reduction in nasal blockage caused by polyps, observed on physical examination, p = 0.005, was mirrored by an increase in nasal IFR (p = 0.0001). Patient rating of the severity and frequency of nasal blockage were reduced more by budesonide than by placebo (p less than or equal to 0.0005). Switching placebo-treated patients to budesonide treatment resulted in a reduction of nasal blockage (p less than 0.001) and an increase in nasal IFR (p less than 0.001). The results demonstrate that topical nasal budesonide, 400 micrograms two times a day, is an effective treatment of nasal polyps.

• Authors: J Ruhno, B Andersson, J Denburg, M Anderson, D Hitch, P Lapp, M Vanzieleghem, J Dolovich
• Journal: The Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 86 Issue 6 Pt 1 Pg. 946-53 (Dec 1990) ISSN: 0091-6749 [Print] United States
• PMID: 2262649 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Glucocorticoids
• Placebos
• Pregnenediones
• Budesonide

Topics

• Administration, Intranasal
• Budesonide
• Double-Blind Method
• Glucocorticoids (therapeutic use)
• Humans
• Nasal Polyps (drug therapy, physiopathology)
• Patient Compliance
• Placebos
• Pregnenediones (adverse effects, therapeutic use)
• Pulmonary Ventilation